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Abstract: 
Introduction: Primary Ewing sarcoma (ES) is a distinctly rare tumour in the kidney and very limited cases were 
reported till date.  
Case Presentation: Herein, we report a case of right renal ES in a young boy who presented with bleeding right 
renal tumour and underwent emergency right radical nephrectomy. Tumour cells are strongly positive for CD99 
and FLI-1, thus confirming the diagnosis.  
Conclusion: Therefore, this entity should always be one of the differential diagnosis while dealing renal masses 
in young population. 
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Introduction 
 Though ES is the second most common malignancy in bone and soft tissue in children and 
young adults, primary extraosseous ES is quite rare, indeed, just more than 100 cases of renal ES has 
been reported till date since first discovery in 1975 [1,2,3]. We report a case of right renal ES in a 
young boy who presented with bleeding right renal tumour and underwent emergency right radical 
nephrectomy in which the tumour cells are strongly positive for CD99 and FLI-1 [4,5]. 
Case report 
 A 19 years old Chinese boy presented with 2 weeks history of worsened right flank pain over 
a 2-month duration associated with low grade fever and abdominal distension. He denied any 
hematuria or recent trauma and other history was unremarkable. He was pale, tachycardic and there 
was right renal angle tenderness on examination. His computed tomography (CT) scan revealed a huge 
(16cm x 16cm x 12cm) heterogenously enhanced right upper-mid pole kidney mass surrounded by 
diffuse perinephric hypodensities and streakiness in upper-middle pole, suggestive of intratumoural 
bleed with extension into right perinephric space. He then underwent emergency right nephrectomy. 
He had uneventful postoperative recovery other than minor partial wound dehiscience. He was well 
upon review in outpatient clinic 1 month postoperatively and referral made to Oncology team for 
further evaluation and possible adjuvant therapy. 
      
 
 
 
 
 
 
 
 
 
 
1(a) 1(b) 
Figure 1 (a) Axial view, (b) coronal view, CT showed large heterogenous mass occupying upper to mid pole of 
right kidney 
 
 
 
 
 
 
 
 
Figure 2 Microscopic photographs showing 
small blue round cells with almost uniform 
morphology in Ewing’s sarcoma (H&E x400). 
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Figure 3 Microscopic photographs showing 
tumour cells are positive for FLI-1 
immunohistochemical stain (x400). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Microscopic photographs showing 
tumour cells are positive for membranous CD-
99 immunohistochemical stain (x400). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Microscopic photographs showing 
tumour cells are positive for vimentin 
immunohistochemical stain (x400). 
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Discussion 
 Renal ES is an aggressive neoplasm that predominantly affects male young adults [6,7,8,9]. 
Kidney sarcomas will usually remain silent until it grows beyond 5.5cm [7,9]. Clinical symptoms are 
indistinctive and the usually clinical findings are pain (85%), palpable mass (60%), and hematuria 
(37%) [8,9,10]. Radiological signs are non-specific and most of the imaging characteristics are 
indistinguishable from renal cell carcinoma (RCC) [6]. This “blue” tumour appears as ill-defined, 
large heterogenous mass with necrotic and hemorrhagic areas. On ultrasonographic examination it 
appears isoechogenic or hypoechogenic to the renal parenchyma, whereas on CT scan, the findings 
include areas of intratumoralhemorrhage or necrosis, peripheral hypervascularity, and diffuse 
calcification [7,8]. Some authors also described venous extension into the renal vein, inferior vena 
cava and right heart [8,11,12]. The differential diagnoses of renal ES are Wilms tumour, 
neuroblastoma, RCC, malignant lymphoma, metastatic renal involvement from sarcoma elsewhere in 
the body, and renal involvement by a primary retroperitoneal sarcoma [7,8]. Diagnosis of renal ES is 
very much rely on pathological findings and immunohistochemical staining. More than 90% of the 
tumours are typically positive for CD99 and FLI-1. CD99 is also positive in synovial sarcoma, 
however it will also show 90% positivity for pancytokeratin which was negative in our case [8,13]. 
Prognosis of disease is poor, with a 5-year survival of 60-70% in localised disease and 20-30% in 
metastatic disease. Common sites of metastasis include lung, liver, abdominal lymph nodes, and bone 
[8,14]. Treatment of primary renal ES includes surgery, chemotherapy and radiotherapy. As primary 
renal ES is an “once a blue moon” disease, till date, there are no standardised treatment protocol for it 
though these patients are generally treated with regimens for other type of ES. Surprisingly, the 
available literature does suggest a high response rate to chemotherapy, especially in local disease 
[14,15]. 
Conclusion 
Primary renal ES is an unusually rare entity with poor prognosis that predominantly affects male 
young adults. Histopathological examination and immunohistochemistry are crucial to ascertain the 
final diagnosis before tailoring a treatment plan.  
Consent 
Patient was well informed that reporting rare disease is crucial in development of medicine and he was 
consented before the writing of this case report. 
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